Avid Bioservices Inc (CDMO)

[JAKE17]

July 23rd will be the start !!!!
6th Annual Anti-Cancer Drug Discovery & Development Summit
Friday, July 23, 2004 8:30 AM ET
Speakers: Phillip Thorpe, Ph.D., Professor, Peregrine Pharmaceuticals, Inc.
Location: Radisson Plaza-Warwick Hotel Philadelphia
Philadelphia, PA

8:30am
Ligand-based Vascular Targeting Agents as Cancer Therapeutics
Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a
rapid and selective shutdown of the blood vessels of tumors. They occlude the preexisting
blood vessels of tumors to cause tumor cell death from ischemia and extensive
hemorrhagic necrosis. Ligand-based VTAs use antibodies, peptides, or growth factors
that bind selectively to tumor versus normal vessels to target tumors with agents that
occlude blood vessels. Major anti-tumor effects in experimental animals have been
obtained with fusion proteins (e.g., vascular endothelial growth factor linked to the
plant toxin gelonin), immunotoxins (e.g., monoclonal antibodies to endoglin
conjugated to ricin A), antibodies linked to cytokines naked antibodies and liposomally
encapsulated cytotoxic drugs. Clinical trials with the first ligand-based VTAs are
imminent.
Philip E. Thorpe, Ph.D., Professor
DEPARTMENT OF PHARMACOLOGY AND SIMMONS CANCER CENTER,
UNIVERSITY OF TEXAS SOUTHWESTERN

http://www.peregrineinc.com/media/pdf/cs300.pdf